🧬 BioMed Pulse · 2026-11-17 02:01 UTC

BIOMED PULSE

Daily Briefing on Longevity, Viruses & New Cures

Tuesday, November 17, 2026 | 02:00 UTC

⚡ TL;DR

The Bundibugyo virus disease outbreak in the Democratic Republic of the Congo has now spread to Kenya and Nigeria and continues at sustained high-level transmission, making it the largest Ebola-family outbreak ever recorded in the DRC — the dominant global health story of the moment. Mood: elevated concern on multiple outbreak fronts, with cautious optimism from new aging-biology and longevity research.

🦠 OUTBREAKS & VIRUSES

BUNDIBUGYO VIRUS DISEASE (DRC, KENYA, NIGERIA) — STILL ESCALATING

  • As of the November 6 WHO Disease Outbreak News, the BVD outbreak in DRC continues at sustained, high-level transmission across multiple health zones, with Kenya and Nigeria now reporting imported cases. [1]
  • The October 23 WHO DON noted geographic expansion within DRC and confirmed the first imported cases in both Kenya and Nigeria; the outbreak has now spread across six of DRC's 26 provinces. [2]
  • As of August 14, WHO described this as the largest Ebola outbreak ever reported in the DRC and noted it was expanding faster than any previous Ebola outbreak on record. [3]
  • The outbreak originated in Mongbwalu health zone, Ituri Province, and has since spread to at least 61 health zones as of the September 10 DON. [4]

MERS-CoV — SAUDI ARABIA AND QATAR

  • Between January 1 and October 5, 2026, Saudi Arabia reported eight laboratory-confirmed MERS-CoV cases including one death across six locations: Al Jouf, Arar, Hafr Al-Batin, Riyadh, Tabuk, and others. [5]
  • Qatar notified WHO on October 29, 2026 of two lab-confirmed MERS cases confirmed on August 5 and August 25, 2026 — the first MERS cases reported from Qatar in this reporting period. [6]

SHAMONDA VIRUS — FIRST DOCUMENTED HUMAN CASE, FRANCE

  • On October 20, 2026, France notified WHO of the first documented human infection with Shamonda virus (SHAV), a rare arbovirus, in an immunocompromised older man from eastern France with no recent travel history. [7]
  • The patient developed severe neurological symptoms; viral characterization is ongoing. [7]

YELLOW FEVER — AFRICA AND AMERICAS

  • Between January 1 and October 12, 2026, the WHO African Region recorded 67 confirmed yellow fever cases including 18 deaths across nine countries: Burkina Faso, Cameroon, Central African Republic, and others. [8]
  • Transmission activity in the Americas persisted into 2026 from an increase that began in 2025, with six countries reporting 79 human infections between January 1 and May 26, 2026. [9]

PNEUMONIA OF UNDETERMINED ETIOLOGY — RUSSIA

  • On October 2, 2026, WHO was notified of the death of an employee of the Irkutsk Antiplague Research Institute of Siberia and the Far East, Russian Federation, following severe pneumonia of undetermined etiology. [10]
  • Investigation is ongoing; WHO flagged the institutional setting — a biosafety research facility — as a point of concern warranting further information from Russian authorities. [10]

NIPAH VIRUS — INDIA

  • In June 2026, Kerala State confirmed one laboratory-confirmed Nipah virus case in Kozhikode district: an adult male who developed neurological symptoms on May 30 and was hospitalized June 10, 2026.

🧬 LONGEVITY & AGING

GDF11 AND MUSCLE AGING — SARCOPENIA MECHANISM CLARIFIED

  • A study published in Genes and Disease found that GDF11 — a circulating factor that declines with age — restores skeletal muscle satellite cell function via the MYC pathway, offering a molecular explanation for how GDF11 may ameliorate sarcopenia.
  • Sarcopenia, the progressive age-related loss of muscle mass and function, is a major driver of frailty and dependency in older adults.

CLINICALAGE — MODELING BIOLOGICAL AGING FROM EHR DATA

  • Researchers publishing in Lancet Digital Health developed ClinicalAge, a framework that models individualized aging trajectories using longitudinal UK electronic health records, validated against mortality and disease outcomes.
  • A linked commentary in Lancet Digital Health described a novel aging biomarker capable of capturing personal aging trajectories from EHR data, moving beyond chronological age as a clinical measure.

AI-BASED BIOLOGICAL AGE FROM FACIAL PHOTOGRAPHS

  • A model development study in Lancet Digital Health (FAHR-Face), led by investigators including Gladyshev VN and Aerts HJ, demonstrated that foundation AI models can estimate biological age and health status from face photographs with meaningful clinical correlation.
  • The approach could enable low-cost, scalable aging assessment at the point of care or in population screening programs.

PHYSICAL ACTIVITY AS AN AGING CLOCK — LANCET HEALTHY LONGEVITY SERIES

  • A series of papers in Lancet Healthy Longevity examined physical function and muscle health as clinically meaningful aging clocks that outperform chronological age in predicting outcomes in older adults.
  • Separate papers in the series reported that physical activity promotion is a public health priority in low- and middle-income countries, and that exercise interventions can be translated from research settings to clinical implementation.
  • A meta-review by King AC and colleagues described multilevel environmental, behavioral, and policy interventions as necessary to build infrastructure for active aging at scale.

ANIMAL PROTEIN, COGNITION, AND DEMENTIA DISPARITIES

  • An ecological analysis published in Future Science OA found associations between animal protein supply, cognitive aging trajectories, and female-to-male dementia disparities at a global level, suggesting dietary protein supply may partially explain geographic and sex-based differences in dementia burden.

SENESCENCE-MIMETIC APPROACH TO TUMOR IMMUNITY

  • A study in Biomaterials (Yang Z et al.) developed hybrid nanovesicle artificial antigen-presenting cells that use senescence-mimetic erythrocyte membranes to direct splenic T-cell priming and display endogenous tumor antigens.
  • The mechanism mimics senescent cell surface characteristics to trigger immune activation — an example of co-opting aging biology for cancer immunotherapy.

SKIN AGING PATHWAY IDENTIFIED IN AMPHIBIAN EXTRACT STUDY

  • Research published in Genes and Disease found that an aqueous extract from the skin secretion of Andrias davidianus (Chinese giant salamander) delays skin aging by suppressing the MAPK signaling pathway in cellular models.
  • The MAPK pathway is a well-established mediator of oxidative stress-driven cellular senescence in skin.

💊 NEW CURES & APPROVALS

OXDERYS (DOXORUBICIN HYDROCHLORIDE) — AVYXA HOLDINGS

  • The FDA processed an original NDA (NDA221093) for Oxderys, a doxorubicin hydrochloride formulation sponsored by Avyxa Holdings, for oncology indications.

GAVRETO (PRALSETINIB) — RIGEL PHARMACEUTICALS

  • The FDA processed a supplemental application for Gavreto (pralsetinib, NDA213721), sponsored by Rigel Pharmaceuticals, a RET kinase inhibitor used in RET-altered non-small cell lung cancer and thyroid cancers.

POHERDY (PERTUZUMAB-DPZB) — SHANGHAI HENLIUS BIOTECH

  • The FDA processed a supplemental BLA (BLA761450) for Poherdy, a pertuzumab biosimilar (pertuzumab-dpzb) from Shanghai Henlius Biotech, for HER2-positive breast cancer indications.

TOFACITINIB CITRATE GENERICS — APOTEX AND DEXCEL

  • Apotex and Dexcel each received original ANDA approvals for tofacitinib citrate (ANDA220458 and ANDA218668 respectively), a JAK inhibitor used for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.

MULTIBIC — FRESENIUS MEDICAL CARE RENAL THERAPIES GROUP

  • The FDA processed an original NDA (NDA219457) for Multibic, a hemodialysis bicarbonate concentrate product from Fresenius Medical Care Renal Therapies Group LLC, for renal replacement therapy.

ZOKINVY (LONAFARNIB) — SENTYNL THERAPEUTICS

  • The FDA processed a supplemental NDA (NDA213969) for Zokinvy (lonafarnib) from Sentynl Therapeutics, a farnesyltransferase inhibitor approved for Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies — rare accelerated aging diseases.

DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE — MICRO LABS

  • The FDA processed a supplemental ANDA (ANDA211466) for the dapagliflozin-metformin combination from Micro Labs, an SGLT2 inhibitor and biguanide combo used in type 2 diabetes management.

🧪 CLINICAL TRIALS

NICE-PAD II — NICOTINAMIDE RIBOSIDE FOR PERIPHERAL ARTERY DISEASE (NCT07782671)

  • This trial is testing whether nicotinamide riboside (NR), an NAD+ precursor with known relevance to mitochondrial and aging biology, improves six-minute walk distance over six months in adults aged 50 and older with peripheral artery disease (PAD), compared to placebo.
  • NR is of significant interest in geroscience as NAD+ levels decline with age and are linked to mitochondrial dysfunction, inflammation, and muscle loss.

PEMBROLIZUMAB FOR NEUROLOGICAL LONG COVID — PHASE I (NCT07388550)

  • A Phase I open-label safety trial (PD1-PASC I) is testing pembrolizumab, a PD-1 checkpoint inhibitor, for neurological post-acute sequelae of SARS-CoV-2, based on the hypothesis that persistent immune dysregulation drives long COVID symptoms.
  • The trial addresses headaches, loss of taste or smell, dizziness, and other chronic neurological symptoms persisting months to years after acute COVID-19.

EXERGAMING PLUS OTAGO EXERCISE PROGRAM — MOBILITY IN OLDER ADULTS (NCT06814678)

  • A clinical trial registered November 16, 2026 is evaluating interactive exergaming combined with the Otago Exercise Program for improving mobility outcomes in community-dwelling adults aged 65 and above.
  • The Otago program is a proven fall-prevention exercise regimen; combining it with exergaming aims to improve adherence and functional outcomes.

EPCORITAMAB FOR WALDENSTROM MACROGLOBULINEMIA (NCT07882173)

  • A trial is evaluating epcoritamab — a CD3xCD20 bispecific antibody — as consolidative therapy for Waldenstrom macroglobulinemia following treatment with Bruton tyrosine kinase inhibitors (BTKi), aiming to deepen remissions in a disease that predominantly affects older adults.

INNOVATIVE ALZHEIMER'S DISEASE CASE FINDING — EHR-BASED (NCT07016178)

  • A trial is testing whether electronic health record data can be used to scalably and equitably identify patients at risk of mild cognitive impairment (MCI) or Alzheimer's disease and related dementias (ADRD) prior to primary care visits.
  • The study aims to improve diverse participation in Alzheimer's care, treatment, and research by reducing diagnostic delays.

BPL-1357 BROAD-SPECTRUM INFLUENZA VACCINE — CHALLENGE STUDY (NCT07215858)

  • A human challenge trial is testing BPL-1357, a broad-spectrum influenza vaccine candidate, against H1N1 virus challenge, aiming to address pandemic preparedness gaps left by seasonal flu vaccines.

📢 PUBLIC HEALTH

CDC DRUG-RESISTANT BACTERIA ALERT

  • A September 2025 CDC report documented a dramatic rise in dangerous drug-resistant bacteria, raising concerns about the pipeline for effective antibiotics.

ANIMAL RABIES ACTIVITY RISING IN THE US

  • CDC issued a statement in September 2026 on increases in animal rabies activity and associated human exposures, urging awareness and prompt post-exposure prophylaxis.

LUNG CANCER PROGRESS DRIVING DOWN US CANCER MORTALITY

  • The 2026 Annual Report to the Nation found that progress against lung cancer is a primary driver of declining overall U.S. cancer mortality rates.

NOTE: This briefing is for informational purposes only and does not constitute medical advice. Always consult a qualified health professional for personal medical decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  2. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  3. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  4. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  5. Middle East respiratory syndrome coronavirus - Kingdom of Saud… — WHO Disease Outbreak News
  6. Middle East respiratory syndrome (MERS) – Qatar — WHO Disease Outbreak News
  7. Shamonda virus in human - France — WHO Disease Outbreak News
  8. Yellow fever - WHO African Region — WHO Disease Outbreak News
  9. Yellow fever - Global — WHO Disease Outbreak News
  10. Pneumonia of undetermined etiology - the Russian Federation — WHO Disease Outbreak News

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20261117-02-v139 · 2026-11-17 02:01 UTC · pulse.uzylab.com